This site uses cookies. For more information, please see our
Privacy Policy
Agree
About
Company
Board
Management
Products
Trogarzo® IV Infusion
Trogarzo® IV Push
TMB-365
TMB-365/TMB-380 (TMB-365 and TMB-380 combination)
Antibody-Drug Conjugates, ADCs
CDMO Service
Contract Development and Manufacturing Service (CDMO)
Partners
News
Activity
Investor Relations
Company
Company Profile
Company Presentation
Corparate Governance
Organization
Board
Committee
Internal Audit
Major Internal Policies
Financials
Monthly Revenue
Financial Reports
Shareholders' Services
Major Shareholders
Dividend Information
Shareholder's Meeting
Sustainable Development
2023 ESG
MENU
(
En
)
En
繁中
Contact CDMO Service
CLOSE
En
繁中
About
Company
Board
Management
Products
Trogarzo® IV Infusion
Trogarzo® IV Push
TMB-365
TMB-365/TMB-380 (TMB-365 and TMB-380 combination)
Antibody-Drug Conjugates, ADCs
CDMO Service
Contract Development and Manufacturing Service (CDMO)
Partners
News
Activity
Investor Relations
Company
Company Profile
Company Presentation
Corparate Governance
Organization
Board
Committee
Internal Audit
Major Internal Policies
Financials
Monthly Revenue
Financial Reports
Shareholders' Services
Major Shareholders
Dividend Information
Shareholder's Meeting
Sustainable Development
2023 ESG
2024
Home
News
Event information
2024
News
Recent News
2024
2023
Event information
2024
2023
Recent News > 2024
Recent News > 2023
Event information > 2024
Event information > 2023
2024/10/30
TaiMed Biologics to Exhibit at BioEurope 2024
2024/07/23
TaiMed Biologics at BIO Asia-Taiwan 2024 (Business updated)
2024/07/10
TaiMed Biologics Showcases Innovative HIV Therapies at BioAsia 2024
2024/05/28
2024 Shareholder Meeting Video Recording
2024/05/28
TaiMed Biologics shared several exciting positive developments at its 2024 shareholders' meeting
2024/05/27
TaiMed to Showcase Innovative HIV Therapies at BIO 2024
2024/04/09
TaiMed is invited to participate in institutional investor conference hosted by MasterLink Securities to share corporate financial information and business outlook